The Productive Innovation Index measures, scores and celebrates a company's ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of first place across the past four years' rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
Takeda was a major mover on the Index this year, rising 14 places to take second place. The principal driver for this change is strong sales growth across the US and emerging markets, having benefitted from a significant number of new drugs in the last 12-18 months in the form of Entyvio® (ulcerative colitis and Crohn's disease), Takecab® (for acid-related GI disorders), Adcetris® (lymphoma) and Brintellix® (major depressive disorder).
Moving up 15 places to third is Denmark's Novo Nordisk. The company continues to occupy leadership positions in front line therapy in type 1 diabetes (T1D) and have a significant share of the type 2 diabetes (T2D) market. This is largely part to strong performances from Victoza® (T2D), Levemir® (T1 and 2D) and the 2015 launch of Tresiba® (for T1 and 2D).
Other high risers inlcude AbbVie, moving up 12 places to fifth and Otsuka, rising from 24th last year to assume ninth place.
Commenting on the index, IDEA Pharma's CEO, Mike Rea said: “Johnson & Johnson continues to be the most successful biopharmaceutical innovator globally. Their strategy of pairing externally sourced innovation with strong internal research, development and commercialisation capabilities has secured the company the top of the Productive Innovation Index for another year. Their strength in maximising success per compound is in no small part due to the ability to match products to patient need. There is no gaming the Productive
Innovation Index – serial success on the Index is achieved by discovering and developing meaningfully great medicines and getting those medicines to patients. It is wonderful to see a company of the scale of Johnson & Johnson that is able to maintain a consistently excellent innovation profile.”
The Productive Innovation Index looks beyond turnover figures and raw approval rates, or more subjective measures of 'innovation'. Instead, it assesses companies based on a range of hard factors including speed to market, attrition rate across phases – in particular phase III, reimbursement rates, regulatory approvals and analyst rankings.
For more information please contact:
Jonathan Crosby
Marketing and Communications Director
IDEA Pharma
Tel: +44 1234 756 343
Mob: +44 7545 538 901
Email: jonathan.crosby@ideapharma.com